Literature DB >> 11994459

Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A.

Miren L Baroja1, Lalitha Vijayakrishnan, Estelle Bettelli, Peter J Darlington, Thu A Chau, Vincent Ling, Mary Collins, Beatriz M Carreno, Joaquín Madrenas, Vijay K Kuchroo.   

Abstract

The catalytic subunit of the serine/threonine phosphatase 2A (PP2A) can interact with the cytoplasmic tail of CTLA-4. However, the molecular basis and the biological significance of this interaction are unknown. In this study, we report that the regulatory subunit of PP2A (PP2AA) also interacts with the cytoplasmic tail of CTLA-4. Interestingly, TCR ligation induces tyrosine phosphorylation of PP2AA and its dissociation from CTLA-4 when coligated. The association between PP2AA and CTLA-4 involves a conserved three-lysine motif in the juxtamembrane portion of the cytoplasmic tail of CTLA-4. Mutations of these lysine residues prevent the binding of PP2AA and enhance the inhibition of IL-2 gene transcription by CTLA-4, indicating that PP2A represses CTLA-4 function. Our data imply that the lysine-rich motif in CTLA-4 may be used to identify small molecules that block its binding to PP2A and act as agonists for CTLA-4 function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994459     DOI: 10.4049/jimmunol.168.10.5070

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus.

Authors:  Bernhard O Boehm; Jeffrey A Bluestone
Journal:  Rev Diabet Stud       Date:  2005-02-10

Review 3.  Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation.

Authors:  Laura L Carter; Beatriz M Carreno
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 4.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 5.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 6.  PP2A as a master regulator of the cell cycle.

Authors:  Nathan Wlodarchak; Yongna Xing
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-02-24       Impact factor: 8.250

7.  The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.

Authors:  Melanie Stumpf; Xuyu Zhou; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

Review 8.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

9.  Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells.

Authors:  Christos Tsatsanis; Katerina Vaporidi; Vassiliki Zacharioudaki; Ariadne Androulidaki; Yuri Sykulev; Andrew N Margioris; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Structure-Function analysis of the CTLA-4 interaction with PP2A.

Authors:  Wendy A Teft; Thu A Chau; Joaquín Madrenas
Journal:  BMC Immunol       Date:  2009-04-30       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.